FDA Adverse Event Injury Summary report: N

REZUM

MDR report key: 20587284 · Received November 1, 2024

Report

Report Number
2124215-2024-66291
Event Type
Injury
Date Received
November 1, 2024
Date of Event
September 1, 2021
Report Date
January 2, 2025
Manufacturer
BOSTON SCIENTIFIC CORPORATION
Product Code
KNS
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
IL, US
Reporter Occupation
PHYSICIAN
Health Professional
Yes

Narratives

Additional Manufacturer Narrative · 0

BLOCK B3: THE EXACT DATE OF THE EVENT IS UNKNOWN. THE PROVIDED EVENT DATE, 09/01/2021, WAS CHOSEN AS THE BEST ESTIMATE BASED ON YEAR THE ARTICLE WAS PUBLISHED. BLOCK G2: LITERATURE SOURCE: MCVARY, K ET AL (2021). FINAL 5 - YEAR OUTCOMES OF THE MULTICENTER RANDOMIZED SHAM - CONTROLLED TRIAL OF A WATER VAPOR THERMAL THERAPY FOR TREATMENT OF MODERATE TO SEVERE LOWER URINARY TRACT SYMPTOMS SECONDARY TO BENIGN PROSTATIC HYPERPLASIA. THE JOURNAL OF UROLOGY. VOL 206, P.P. 715-724. 0022-5347/21/2063-0716/0.

Additional Manufacturer Narrative · 0

THE DEVICE IS NOT AVAILABLE FOR ANALYSIS; THEREFORE, NO PHYSICAL ANALYSIS OF THE PRODUCT COULD BE PERFORMED. THERE WAS NO REPORT OF A DEVICE ALLEGATION. THE REPORTED PATIENT'S SYMPTOMS ARE KNOWN RISK ASSOCIATED WITH THIS DEVICE TYPE AND INDICATED AS SUCH IN THE INSTRUCTIONS FOR USE (IFU) BLOCK B3: THE EXACT DATE OF THE EVENT IS UNKNOWN. THE PROVIDED EVENT DATE, 09/01/2021, WAS CHOSEN AS THE BEST ESTIMATE BASED ON YEAR THE ARTICLE WAS PUBLISHED. BLOCK G2: LITERATURE SOURCE MCVARY, K ET AL (2021). FINAL 5 - YEAR OUTCOMES OF THE MULTICENTER RANDOMIZED SHAM - CONTROLLED TRIAL OF A WATER VAPOR THERMAL THERAPY FOR TREATMENT OF MODERATETO SEVERE LOWER URINARY TRACT SYMPTOMS SECONDARY TO BENIGN PROSTATIC HYPERPLASIA. THE JOURNAL OF UROLOGY. VOL 206, P.P. 715-724. 0022-5347/21/2063-0716/0.

Description of Event or Problem · 0

IT WAS REPORTED TO BOSTON SCIENTIFIC AN ARTICLE PUBLISHED IN THE JOURNAL OF UROLOGY, THAT A MULTICENTER STUDY WAS CONDUCTED AT 15 CENTERS IN THE UNITED STATES, WITH A FOLLOW UP PERIOD OF 5 YEARS. THE DATA OF 197 PATIENTS UNDERWENT VAPOR TREATMENTS, ONLY THE DATA FROM 77 SUBJECTS WERE ANALYZED. THE MOST COMMON ADVERSE EVENTS RELATED TO DEVICE OR PROCEDURE WERE DYSURIA, GROSS HEMATURIA, HEMATOSPERMIA, URINARY FREQUENCY, ACUTE URINARY RETENTION, UNCONFIRMED URINARY TRACT INFECTION, AND DECREASED IN EJACULATORY VOLUME. THESE ADVERSE EVENTS RESOLVED EITHER SPONTANEOUSLY OR WITH ROUTINE TREATMENT. NO ADVERSE EVENTS OCCURRED FROM YEARS 1 TO 5. DURING THE TIME OF THIS STUDY, 11.1% SUBJECTS OF THE TREATMENT ARM REQUIRED BPH MEDICATION AND 4.4% OF THE SUBJECTS REQUIRED SURGICAL RE-TREATMENT.

Description of Event or Problem · 0

IT WAS REPORTED TO BOSTON SCIENTIFIC AN ARTICLE PUBLISHED IN THE JOURNAL OF UROLOGY, THAT A MULTICENTER STUDY WAS CONDUCTED AT 15 CENTERS IN THE UNITED STATES, WITH A FOLLOW UP PERIOD OF 5 YEARS. THE DATA OF 197 PATIENTS UNDERWENT VAPOR TREATMENTS, ONLY THE DATA FROM 77 SUBJECTS WERE ANALYZED. THE MOST COMMON ADVERSE EVENTS RELATED TO DEVICE OR PROCEDURE WERE DYSURIA, GROSS HEMATURIA, HEMATOSPERMIA, URINARY FREQUENCY, ACUTE URINARY RETENTION, UNCONFIRMED URINARY TRACT INFECTION, AND DECREASED IN EJACULATORY VOLUME. THESE ADVERSE EVENTS RESOLVED EITHER SPONTANEOUSLY OR WITH ROUTINE TREATMENT. NO ADVERSE EVENTS OCCURRED FROM YEARS 1 TO 5. DURING THE TIME OF THIS STUDY, 11.1% SUBJECTS OF THE TREATMENT ARM REQUIRED BPH MEDICATION AND 4.4% OF THE SUBJECTS REQUIRED SURGICAL RE-TREATMENT.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
631524 REZUM UNIT, ELECTROSURGICAL ENDOSCOPIC (WITH OR WITHOUT ACCESSORIES) KNS BOSTON SCIENTIFIC CORPORATION

Patients

Seq Age Sex Outcome Treatment
1 NA Unknown Required Intervention